Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS). (April 2017) - Chaurasia, P.; Isoda, F.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.P.; Reddy, E.P.; Silverman, L.R.